Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Cancer Statistics, 2007

2007 • 7,372 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

1991 • 2,774 citations

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

1996 • 2,766 citations

Cancer of the Ovary

2004 • 2,075 citations

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

1997 • 1,590 citations

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

2000 • 1,536 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

2007 • 879 citations

Role of vascular endothelial growth factor in the regulation of angiogenesis

1999 • 733 citations

Clinical Implications of Circulating Angiogenic Factors in Cancer Patients

2001 • 599 citations

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

2003 • 588 citations

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

2002 • 494 citations

Maximally Selected Chi Square Statistics

1982 • 480 citations

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

2003 • 416 citations

Redefining the Target: Chemotherapeutics as Antiangiogenics

2001 • 397 citations

Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice

1998 • 377 citations

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

2005 • 364 citations

Vascular endothelial growth factor expression in early stage ovarian carcinoma

1997 • 364 citations

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

1997 • 356 citations

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

2005 • 347 citations

Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease

1996 • 341 citations

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

2002 • 313 citations

Vascular permeability factor gene expression in normal and neoplastic human ovaries.

1994 • 259 citations

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

2005 • 257 citations

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

2002 • 241 citations

Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents

1994 • 241 citations

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

2005 • 218 citations

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

2000 • 204 citations

Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.

1996 • 203 citations

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

2006 • 195 citations

Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression

2004 • 184 citations

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.

2001 • 182 citations

Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.

1995 • 165 citations

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

2004 • 159 citations

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.

2001 • 153 citations

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

2006 • 125 citations

Maximally Selected Chi Square Statistics for Small Samples

1982 • 121 citations

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

2006 • 111 citations

Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future Research

2002 • 94 citations

GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma

2006 • 88 citations

Angiogenesis in primary and metastatic epithelial ovarian carcinoma

1997 • 87 citations

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

2003 • 85 citations

Aquaporins and the respiratory system: advice for a lung investigator

2000 • 78 citations

Tamoxifen therapy of epithelial ovarian cancer

1986 • 67 citations

Bevacizumab in patients with advanced platinum-resistant ovarian cancer

2006 • 65 citations

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

2005 • 55 citations

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

2005 • 37 citations

Bevacizumab, when Added to Paclitaxel/Carboplatin, Prolongs Survival in Previously Untreated Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Results from the ECOG 4599 Trial

2005 • 32 citations

Tumour angiogenesis: pathophysiology and clinical significance

1996 • 18 citations

Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamide

1990 • 9 citations

Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial

2006 • 5 citations